Rayson, D.; Gandhi, S.; Joy, A.A.; Brezden-Masley, C.; Gelmon, K.A.; Sehdev, S.; Cescon, D.; Chia, S.
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895.
https://doi.org/10.3390/curroncol29120778
AMA Style
Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, Cescon D, Chia S.
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Current Oncology. 2022; 29(12):9891-9895.
https://doi.org/10.3390/curroncol29120778
Chicago/Turabian Style
Rayson, Daniel, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, and Stephen Chia.
2022. "Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain" Current Oncology 29, no. 12: 9891-9895.
https://doi.org/10.3390/curroncol29120778
APA Style
Rayson, D., Gandhi, S., Joy, A. A., Brezden-Masley, C., Gelmon, K. A., Sehdev, S., Cescon, D., & Chia, S.
(2022). Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Current Oncology, 29(12), 9891-9895.
https://doi.org/10.3390/curroncol29120778